Environmental, Social And Governance Report

Overview

The report describes Grand Pharma's 2024 ESG governance and performance across a broad standalone disclosure covering governance, patient well-being, employees, climate, resources, pollution, supply chain and community investment. It explicitly applies double materiality and places ultimate ESG responsibility with the Board. Environmental highlights include 505,301.12 tCO2e of Scope 1 and 2 emissions and a target to reduce GHG emission intensity by 10% from the 2023 base year by 2030. The report also discloses 12,455 employees and extensive 2024 safety, training, resource-use and social-welfare information.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services

Overview